-

SELECT MEDICAL STOCK ALERT: Does $16.50 Per Share Represent a Fair Shareholder Buyout Price? Kaskela Law Firm Announces Investigation into Fairness of Buyout Offer and Encourages Investors to Contact the Firm – SEM

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC is investigating the recently announced buyout of Select Medical Holdings Corp. (“Select Medical”) (NYSE: SEM) shareholders to determine whether the $16.50 per share buyout offer is fair to the company’s investors or if it undervalues the company’s shares.

Kaskela Law is investigating the recently announced buyout of Select Medical Holdings Corp. (NYSE: SEM) shareholders to determine whether the $16.50 per share buyout offer is fair to the company’s investors or if it undervalues the company's shares.

Share

Click here for additional information: https://kaskelalaw.com/case/select-medical/

On March 2, 2026, Select Medical announced that it had agreed to be acquired by an investment consortium at a price of $16.50 per share in cash. Following the closing of the proposed transaction the company’s shares will no longer be publicly traded.

The investigation seeks to determine whether investors will be receiving sufficient financial consideration for their Select Medical shares, and whether the company’s representatives breached their fiduciary duties in agreeing to the $16.50 per share buyout price. Notably, at the time the proposed transaction was announced, at least one stock analyst was maintaining a price target for Select Medical’s shares of $19.00 per share.

The investigation seeks to determine whether investors will be receiving sufficient financial consideration for their Select Medical shares, and whether the company’s representatives breached their fiduciary duties in agreeing to the $16.50 per share buyout price.

Select Medical investors who would like to learn more about the investigation and their legal rights and options are encouraged to contact lead investigative attorney Adrienne Bell, Esq. at (484) 229-0750 or by email at abell@kaskelalaw.com. You can also click on the following link or paste it into your browser to learn more:

https://kaskelalaw.com/case/select-medical/

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation in contingent litigation. For additional information about Kaskela Law LLC, including the firm's recent notable recoveries for investors, please visit www.kaskelalaw.com.

This communication may constitute attorney advertising in certain jurisdictions.

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 - 0750
www.kaskelalaw.com

Kaskela Law LLC 

NYSE:SEM

Release Versions

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(484) 229 - 0750
www.kaskelalaw.com

More News From Kaskela Law LLC 

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company’s current shareholders. The investigation seeks to determine whether Amneal or the company’s officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional infor...

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th...

Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company’s stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor...
Back to Newsroom